Federal award (DEFINITIVE CONTRACT, fiscal year 2024)
Recipient: NOVOMEDIX LLC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2025-09-15 to 2027-09-14
Current total value of award: $2977013
Description: SBIR PHASE II - ENHANCED OVERALL SURVIVAL IN HIGH-RISK PEDIATRIC SOLID TUMORS USING A NOVEL ORAL SMALL MOLECULE